Inhibition of L-arginine metabolizing enzymes by L-arginine-derived advanced glycation end products

Journal of Clinical Biochemistry and Nutrition

Volumn 46, Issue 2, 2010, Pages 177-185

  Lai, Ying Ling ^a,b   Aoyama, Sae ^a   Nagai, Ryoji ^c   Miyoshi, Noriyuki ^a   Ohshima, Hiroshi ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

^c JAPAN WOMEN'S UNIVERSITY   (Japan)

Author keywords

Advanced glycation end products; Arginase; Dimethylarginine dimethylaminohydrolase; N carboxymethyl arginine; Nitric oxide synthase

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ARGINASE; ARGININE; CITRULLINE; DIMETHYLARGININASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENZYME; INDUCIBLE NITRIC OXIDE SYNTHASE; N(G) METHYLARGININE; N(G),N(G) DIMETHYLARGININE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE;

ANIMAL TISSUE; ARTICLE; BIOAVAILABILITY; CATALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SYNTHESIS; HYDROLYSIS; IC 50; IN VITRO STUDY; NONHUMAN; PROTEIN DEGRADATION; RAT;

EID: 77949813688     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.09-104     Document Type: Article

References (36)

1. Brownlee, M., Cerami, A., and Vlassara, H.: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med., 318, 1315-1321, 1988.
2. Kiuchi, K., Nejima, J., Takano, T., Ohta, M., and Hashimoto, H.: Increased serum concentrations of advanced glycation end products: a marker of coronary artery disease activity in type 2 diabetic patients. Heart, 85, 87-91, 2001.
3. Bucala, R., Tracey, K.J., and Cerami, A.: Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J. Clin. Invest., 87, 432-438, 1991.
4. Lauer, T., Rassaf, T., Planitz, C., Preuss, R., Krause, R., Henle, T., and Deussen, A.: Evidence against nitric oxide-quenching effects of chemically defined Maillard reaction products. Horm. Metab. Res., 40, 233-238, 2008.
5. Chakravarthy, U., Hayes, R.G., Stitt, A.W., McAuley, E., and Archer, D.B.: Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. Diabetes, 47, 945-952, 1998.
6. Xu, B., Ji, Y., Yao, K., Cao, Y.X., and Ferro, A.: Inhibition of human endothelial cell nitric oxide synthesis by advanced glycation end-products but not glucose: relevance to diabetes. Clin. Sci., 109, 439-446, 2005.
7. Xu, B., Chibber, R., Ruggiero, D., Kohner, E., Ritter, J., and Ferro, A.: Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J., 10, 1289-1291, 2003.
8. Thornalley, P.J., Langborg, A., and Minhas, H.S.: Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem. J., 344, 109-116, 1999.
9. Babaei-Jadidi, R., Karachalias, N., Ahmed, N., Battah, S., and Thornalley, P.J.: Prevention of Incipient Diabetic Nephropathy by High-Dose Thiamine and Benfotiamine. Diabetes, 52, 2110-2120, 2003.
10. Iijima, K., Murata, M., Takahara, H., Irie, S., and Fujimoto, D.: Identification of N(omega)-carboxymethylarginine as a novel acid-labile advanced glycation end product in collagen. Biochem. J., 347, 23-27, 2000.
11. Gruber, P. and Hofmann, T.: Chemoselective synthesis of peptides containing major advanced glycation end-products of lysine and arginine. J. Pept Res., 66, 111-124, 2005.
12. Westwood, M.E. and Thornalley, P.J.: Molecular characteristics of methylglyoxal-modified bovine and human serum albumins. Comparison with glucose-derived advanced glycation endproduct-modified serum albumins. J. Protein Chem., 14, 359-372, 1995.
13. Odani, H., Iijima, K., Nakata, M., Miyata, S., Kusunoki, H., Yasuda, Y., Hiki, Y., Irie, S., Maeda, K., and Fujimoto, D.: Identification of N(omega)-carboxymethylarginine, a new advanced glycation endproduct in serum proteins of diabetic patients: possibility of a new marker of aging and diabetes. Biochem. Biophys. Res. Commun., 285, 1232-1236, 2001.
14. Mera, K., Fujiwara, Y., Otagiri, M., Sakata, N., and Nagai, R.: Immunological detection of N omega-(Carboxymethyl) arginine by a specific antibody. Ann. NY Acad. Sci., 1126, 155-157, 2007.
15. Förstermann, U., Closs, E.I., Pollock, J.S., Nakane, M., Schwarz, P., Gath, I., and Kleinen, H.: Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension, 23, 1121-1131, 1994.
16. Alderton, W.K., Cooper, C.E., and Knowles, R.G.: Nitric oxide synthases: structure, function and inhibition. Biochem. J., 357, 593-615, 2001.
17. Surdacki, A., Nowicki, M., Sandmann, J., Tsikas, D., Boeger, R.H., Bode-Boeger, S.M., Kruszelnicka-Kwiatkowska, O., Kokot, F., Dubiel, J.S., and Froelich, J.C.: Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J. Cardiovasc. Pharmacol., 33, 652-658, 1999.
18. Vallance, P., Leone, A., Calver, A., Collier, J., and Moncada, S.: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet, 339, 572-575, 1992.
19. Fard, A., Tuck, C.H., Donis, J.A., Sciacca, R., Di Tullio, M.R., Wu, H.D., Bryant, T.A., Chen, N.T., Torres-Tamayo, M., Ramasamy, R., Berglund, L., Ginsberg, H.N., Homma, S., and Cannon, P.J.: Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes. Arterioscler. Thromb. Vase. Biol., 20, 2039-2044, 2000.
20. Ogawa, T., Kimoto, M., and Sasaoka, K.: Purification and properties of a new enzyme, NG,NG-dimethylarginine dimethylaminohydrolase, from rat kidney. J. Biol. Chem., 264, 10205-10209, 1989.
21. MacAllister, R.J., Parry, H., Kimoto, M., Ogawa, T., Russell, R.J., Hodson, H., Whitley, G.S., and Vallance, P.: Regulation of nitric oxide synthesis by dimethylarginine dimethylamino-hydrolase. Br. J. Pharmacol., 119, 1533-1540, 1996.
22. Lin, K.Y., Ito, A., Asagami, T., Tsao, R.S., Adimoolam, S., Kimoto, M., Tsuji, H., Reaven, G.M., and Cooke, J.P.: Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation, 106, 987-992, 2002.
23. Wu, G. and Morris, S.M. Jr.: Arginine metabolism: nitric oxide and beyond. Biochem. J., 336, 1-17, 1998.
24. Pieper, G.M. and Dondlinger, L.A.: Plasma and vascular tissue arginine are decreased in diabetes: acute arginine supplementation restores endothelium-dependent relaxation by augmenting cGMP production. J. Pharmacol. Exp. Ther., 283, 684-691, 1997.
25. Hagenfeldt, L., Dahlquist, G., and Persson, B.: Plasm a amino acids in relation to metabolic control in insulin-dependent diabetic children. Acta Paediatr. Scand., 78, 278-282, 1989.
26. Alt, N. and Schieberle, P.: Model studies on the influence of high hydrostatic pressure on the formation of glycated arginine modifications at elevated temperatures. J. Agric. Food Chem., 53, 5789-5797, 2005.
27. Aoyama, C., Santa, T., Tsunoda, M., Fukushima, T., Kitada, C., and Imai, K.: A fully automated amino acid analyzer using NBD-F as a fluorescent derivatization reagent. Biomed. Chromatogr., 18, 630-636, 2004.
28. Imamura, M., Waseda, Y., Marinova, G.V., Ishibashi, T., Obayashi, S., Sasaki, A., Nagai, A., and Azuma, H.: Alterations of NOS, arginase, and DDAH protein expression in rabbit cavernous tissue after administration of cigarette smoke extract. Am. J. Physiol. Regul. Integr. Comp. Physiol., 293, R2081-R2089, 2007.
29. Loyaga-Rendon, R.Y., Sakamoto, S., Beppu, M., Aso, T., Ishizaka, M., Takahashi, R., and Azuma, H.: Accumulated endogenous nitric oxide synthase inhibitors, enhanced arginase activity, attenuated dimethylarginine dimethylamino-hydrolase activity and intimai hyperplasia in premenopausal human uterine arteries. Atherosclerosis, 178, 231-239, 2005.
30. Boucher, J.L., Custot, J., Vadon, S., Delaforge, M., Lepoivre, M., Tenu, J.P., Yapo, A., and Mansuy, D.: N omega-hydroxyl-L-arginine, an intermediate in the L-arginine to nitric oxide pathway, is a strong inhibitor of liver and macrophage arginase. Biochem. Biophys. Res. Commun., 203, 1614-1621, 1994.
31. Thornalley, P.J., Battah, S., Ahmed, N., Karachalias, N., Agalou, S., Babaei-Jadidi, R., and Dawnay, A.: Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem. J., 375, 581-592, 2003.
32. Böger, R.H.: The emerging role of asymmetric dimethyl-arginine as a novel cardiovascular risk factor. Cardiovasc. Res., 59, 824-833, 2003.
33. Vallance, P. and Leiper, J.: Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine dimethyl-aminohydrolase pathway. Arterioscler. Thromb. Vase. Biol., 24, 1023-1030, 2004.
34. Leiper, J.M., Santa Maria, J., Chubb, A., MacAllister, R.J., Charles, L.G., Whitley, G.S., and Vallance, P.: Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem. J., 343, 209-214, 1999.
35. Sorrenti, V., Mazza, F., Campisi, A., Vanella, L., Li, Volti, and DiGiacomo, C.: High glucose-mediated imbalance of nitric oxide synthase and dimethylarginine dimethylamino-hydrolase expression in endothelial cells. Curr. Neurovasc. Res., 3, 49-54, 2006.
36. Boucher, J.L., Moali, C., and Tenu, J.P.: Nitric oxide biosynthesis, nitric oxide synthase inhibitors and arginase competition for L-arginine utilization. Cell Mol. Life Sci., 55, 1015-1028, 1999.